Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Pfizer ( PFE 1.46%) made a fortune thanks to its work in the COVID-19 market. In 2022, it became the first company in the ...

Pfizer Inc. closed 25.65% short of its 52-week high of $31.54, which the company achieved on July 30th.

Last year was a strong year in terms of performance and execution by Pfizer, even though its stock took a hit in 2023 due to the decline in revenues and profits. It saw improved performance of its ...

It compares these trends to the stock’s performance during the 2008 recession. In contrast, here’s how PFE stock and the broader market performed during the 2007/2008 crisis. PFE stock ...

The company's financial performance is recovering faster ... initiatives could serve as a positive catalyst for the stock. Additionally, Pfizer might exceed its announced $4 billion savings ...

MRNA stock Vs. PFE stock YTD performance (as of 31 Aug 21). Therefore, with both companies having their fair share of success in the COVID-19 market, we are rather surprised (although as MRNA ...

PFE) stock price could rebound over a one-month period after falling 4% in a week, based on its historical performance. However, PFE stock has seen a decline of over 6% since then, and it is down ...

Let’s understand the company’s strengths and weaknesses to better analyze how to play PFE’s stock in the post-earnings scenario. Sales of PFE’s COVID Products Decline With the end of the ...